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Amyloid- (A) accumulation and aggregation are
thought to contribute to the pathogenesis of Alzheimer’s
disease (AD). In AD, there is a selective decrease in the
numbers of radioligand binding sites corresponding to
the most abundant nicotinic acetylcholine receptor
(nAChR) subtype, which contains human 4 and 2 sub-
units (h42-nAChR). However, the relationships be-
tween these phenomena are uncertain, and effects of A
on h42-nAChR function have not been investigated in
detail. We first confirmed expression of h4 and h2
subunits as messenger RNA in transfected, human SH-
EP1 cells by reverse transcription-polymerase chain re-
action and mRNA fluorescence in situ hybridization
analyses. Immunoprecipitation Western analyses con-
firmed 4 and 2 subunit protein expression and co-
assembly. Whole cell current recording demonstrated
heterologous expression in SH-EP1-h42 cells of func-
tional h42-nAChRs with characteristic responses to
nicotinic agonists or antagonists. Nicotine-induced
whole cell currents were suppressed by A1–42 in a dose-
dependent manner. Functional inhibition was selective
for A1–42 compared with the functionally inactive, con-
trol peptide A40–1. A1–42-mediated inhibition of h42-
nAChR function was non-competitive, voltage-indepen-
dent, and use-independent. Pre-loading of cells with
guanyl-5-yl thiophosphate failed to prevent A1–42-in-
duced inhibition, suggesting that down-regulation of
h42-nAChR function by A1–42 is not mediated by
nAChR internalization. Sensitivity to A1–42 antagonism
at 1 nM was evident for h42-nAChRs, but not for het-
erologously expressed human 7-nAChRs, although
both nAChR subtypes were functionally inhibited by 100
nM A1–42, with the magnitude of functional block being
higher for 100 nM A1–42 acting on h7-nAChRs. These
findings suggest that h42-nAChRs are sensitive and
perhaps pathophysiologically relevant targets for A
neurotoxicity in AD.
Alzheimer’s disease (AD)1 is a progressive, neurodegenera-
tive disorder manifest as a severe impairment of learning and
memory. Pathophysiological hallmarks of AD include extracel-
lular deposits of -amyloid peptide (A) in senile plaques, for-
mation of intraneuronal neurofibrillary tangles, and choliner-
gic neuron death (1). Although the precise mechanisms of AD
pathogenesis are only partially understood, it is now widely
accepted that the accumulation and aggregation of A1–42
plays a key role in the disease (2). Evidence has indicated an
interaction between A and the cholinergic system (3). For
example, very low concentrations (pico to nanomolar) of A can
directly induce cholinergic hypofunction (4–6). It has been
reported that solubilized A inhibits several steps of acetylcho-
line synthesis and release (4, 7), inhibits cholinergic enzyme
activity (6), impairs cholinergic metabolism and neurotrans-
mission (8–10), and depresses hippocampal synaptic function
(11).
Recent evidence suggests possible roles for nicotinic acetyl-
choline receptors (nAChRs) as central targets for A-induced
neurotoxicity manifest as cholinergic hypofunction and cogni-
tive impairment. First, in the brain of AD patients, there is a
marked decrease in the numbers of nAChR radioligand binding
sites (12), particularly those that have the highest affinity for
nicotine and appear to be the most abundant nAChR subtype in
the brain of vertebrates (13–16). Immunoassays show that
these nAChRs contain 4 and 2 subunits (17, 18). Second,
nAChR 4 and 2 subunit immunoreactivity is localized in AD
brain to A plaques and neurofibrillary tangles (19). Third,
interactions have been reported of A1–42 with radioligand
binding sites on another abundant nAChR subtype found in the
vertebrate brain containing 7 subunits (7-nAChR; picomolar
affinity) and on presumed 42-nAChR subtypes (nanomolar
affinity) (20, 21). Direct inhibition to some extent of 7-nAChR
function by A has been demonstrated in whole cell current
and excised membrane patch single channel recordings from
interneurons in rat hippocampal slices (22), in whole cell stud-
ies using rat hippocampal cultured neurons (23), and in whole
cell recordings from Xenopus oocytes containing heterologously
expressed rat or human 7-nAChRs (24, 25), although one
report describes that picomolar concentrations of A directly
activated whole cell current responses of Xenopus oocytes het-
erologously expressing rat 7-nAChRs (26). Fourth, it is well
known that nAChRs participate in cognitive functions, includ-
ing learning and memory (16), which are compromised in ani-
mals lacking 4 or 2 subunits (27, 28). Thus, nAChR agonists,
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antagonists, and modulators have received attention as poten-
tially novel agents for therapeutic use in AD (29–31).
However, surprisingly little attention has been given to the
possible functional effects of A on the function of human (h)
42-nAChRs. To fill this gap in knowledge, we employed
patch clamp techniques to elucidate the acute effects of A1–42,
control peptide, or related peptides on the function of h42-
nAChRs heterologously expressed in the SH-EP1 cell line.
EXPERIMENTAL PROCEDURES
Heterologously Expressed h42-nAChRs in SH-EP1 Cells—Human
4 and 2 subunits (kindly provided by Dr. Ortrud Steinlein, Institute for
Human Genetics, Rheinische-Wilhelms-Universitat, Bonn, Germany)
were subcloned into pcDNA3.1-zeocin and pcDNA3.1-hygromycin vectors,
respectively, and transfected using established techniques (32–34) into
native nAChR-null SH-EP1 cells (35) to create the SH-EP1-h42 cell
line. For this and all other methods, manipulations were conducted at
room temperature (23  1 °C) unless otherwise noted. Briefly, 3 million
SH-EP1 cells in 0.5 ml of 20 mM HEPES, 87 mM NaCl, 5 mM KCl, 0.7 mM
NaHPO4, 6 mM dextrose, pH 7.05, in an electroporation cuvette were
mixed with 100 g of 4 and 2 subunit cDNA constructs. Samples were
subjected to electroporation (Bio-Rad Gene Pulsar model 1652076) at 960
microfarads and 200 volts. After electroporation, cells were suspended to
5 ml in complete medium (36), and 1-ml aliquots were added to 12-ml
aliquots of medium in each of five 100-mm dishes before returning the
cells to an incubator at 37 °C. 48 h later, positive selection of incubated
cells was initiated by supplementing the medium with 0.25 mg/ml zeocin
(Invitrogen) and 0.4 mg/ml hygromycin (Calbiochem). Colonies of surviv-
ing cells were picked by ring cloning and expanded before being screened
for radioligand binding and functional evidence for 42-nAChR expres-
sion, which led to selection of the clone designated as the SH-EP1-h42
cell line. Cells were maintained as low passage in medium with 0.25
mg/ml zeocin and 0.4 mg/ml hygromycin to ensure stable expression of
phenotype and passaged once weekly by splitting just-confluent cultures
1/10 to maintain cells in proliferative growth. Studies also were done
using another cell line transfected with the human 4 subunit cDNA and
a chimeric 2 subunit cDNA encoding nAChR 2 subunit sequences,
except for cytoplasmic loop amino acids sequence Lys336-Ser448, which was
replaced by amino acids Arg347-Ala448 from the murine serotonin receptor
5-TH3A subunit sequence via a process described in detail elsewhere (37).
RNA Preparation and Reverse Transcription (RT)-PCR—Total RNA
was isolated from the cells growing at 80% confluency in a 100-mm
culture dish using 2 ml of TRIzolTM reagent (Invitrogen). Prior to
RT-PCR, RNA preparations were treated with amplification-grade
RNase-free DNase (Invitrogen) to remove residual genomic DNA con-
tamination. Typically, 1 g of RNA was incubated with 1 unit of DNase
I in a 10 l-reaction at room temperature for 15 min, and the DNase I
was subsequently inactivated by addition of 1 l of 25 mM EDTA and
incubation at 65 °C for 10 min. RT was carried out using 0.8 g of
DNA-free total RNA and oligo(dT)12–18 primer in a 20-l reaction using
the Superscript IITM Preamplification system (Invitrogen). At the end of
the RT reaction, reverse transcriptase was deactivated by incubation at
75 °C for 10 min, and RNAs were removed by adding 1 unit of RNase H
followed by incubation at 37 °C for 30 min. A typical PCR was per-
formed using 2 l of cDNA preparation, 1 l of 10 M each of 5 and 3
gene-specific primers, 1 l of 10 mM dNTP, and 2.5 units of RedTaqTM
(Sigma) in a 50-l reaction. The primers used in the amplification stage
were designed and synthesized based on published gene sequences
(GenBankTM accession numbers: 4, L35901; 2, X53179; GAPDH,
M32599). The primer sequences and their predicted product sizes are:
nAChR, 4 subunit sense 5-gaatgtcacctccatccgcatc-3, 4 antisense
5-ccggca(a/g)ttgtc(c/t)ttgaccac-3 (product size 790 bp); nAChR, 2 sub-
unit sense 5-cggctcccttccaaacaca-3, 2 antisense 5-gcaatgatggcgtggct-
gctgca-3 (product size 754 bp); GAPDH, sense 5-cgtattgggcgcctggtcac-
cag-3, GAPDH antisense 5-gtccttgcccacagccttggcagc-3 (product size
624 bp). Amplification reactions were carried out in a RoboCycler
(Stratagene, La Jolla, CA) for 35 amplification cycles at 95 °C for 1 min,
55 °C for 90 s, and 72 °C for 90 s, followed by an additional 4-min
extension at 72 °C. One-tenth of each RT-PCR product was then re-
solved on a 1% agarose gel before ethidium staining was used to visu-
alize bands under ultraviolet illumination.
In Situ Hybridization for Cell-specific Localization of 4 or 2 Sub-
unit Message—Riboprobes corresponding to nucleotide sequences cod-
ing for large segments of the 4 or 2 subunit large cytoplasmic do-
mains were prepared from in vitro transcription and used for in situ
hybridization. For riboprobe preparation, 354- (for the 4 subunit) or
211-bp (for the 2 subunit) partial cDNA fragments were amplified
from human nAChR 4 and 2 subunit cDNA constructs using the
following two sets of PCR primers: 4 sense 5-gcacccgccctcaccgtccttc-3
and 4 antisense 5-tcagccgagtgggtgttgcgagag-3; 2 sense 5-catcatt-
gcgcccgtcagcg-3 and 2 antisense 5-gccacagccacacggctccc-3. These 4
and 2 subunit cytoplasmic domain templates were then gel purified
and non-directionally ligated to a T7 phage promoter adapter (Lig’n
Scribe, Ambion, Austin, TX). Subsequent PCRs using sense or anti-
sense gene-specific primers in conjunction with Lig’n Scribe adapter
primers were then performed to selectively amplify ligation products of
in vitro transcription templates in antisense or sense orientation. Sense
or antisense partial 4/2 RNAs were separately transcribed from the
PCR-derived template in the presence of biotinylated UTPs using the
MAXIscript in vitro transcription system (Ambion), and the quality and
quantity of the riboprobes were evaluated using denaturing polyacryl-
amide gel electrophoresis and spectrophotometric reading, respectively.
For cell sample preparation, confluent SH-EP1-h42 cells were
trypsinized, resuspended in medium, seeded on Lab Tek II CC2 cham-
bered slides at a target density of 50,000 cells/chamber, and allowed
to grow at 37 °C to achieve proper morphology and optimal confluence
(90%). After 2 days, cells were then briefly rinsed in 1 phosphate-
buffered saline (PBS), fixed in 4% paraformaldehyde, rinsed again in
1 PBS for 5 min, and acetylated, delipidated with chloroform, and
serially dehydrated with ethanol (50, 75, 85, and 95%) at 23  1 °C.
Samples were then incubated in pre-hybridization solution containing
final concentrations of 250 g/ml tRNA, 25% formamide, 10% dextran
sulfate, 2.5 Denhardt’s solution, 0.05 mg/ml salmon sperm DNA, 4
SSCP, 4 mM EDTA, pH 8.0, for 2 h at 50 °C before being incubated in
hybridization solution containing antisense or sense probes (final con-
centration ranging from 0.2 to 0.7 ng/l) for 20 h at 50 °C. After
hybridization, samples were rinsed in 2 SSC twice for 5 min each, 1
SSC for 10 min, 0.5 SSC for 10 min at 23  1 °C, 0.1 SSC for 20 min
at 60 °C, and briefly rinsed in double distilled water at 23  1 °C.
Samples were then dehydrated again in a graded ethanol series and
vacuum dried under desiccant. Dry samples were then rehydrated by
rinsing in 1 PBS for 5 min before submersion in a 1:2000 dilution (in
1 PBS supplemented with 0.1% bovine serum albumin) of avidin-
Alexa fluorophore complexes (Molecular Probes, Eugene, OR) for 30
min. To terminate the reaction, samples were rinsed 3 times in 1 PBS
for 15 min each, again at 23  1 °C. Slides were then coverslipped and
stored at 4 °C in the dark until being subjected to fluorescence micros-
copy (Olympus IX70, Melville, NY) and image analysis using ImagePro
Plus version 4.1 (Silver Spring, MD).
Immunoprecipitation-Western Analysis for Confirmation of 4 and
2 Subunit Assembly—Preparation of non-ionic detergent-solubilized
membranes for immunoprecipitation began with medium removal from
100-mm dishes containing plated cells, rinsing of dishes 3 times with
NP buffer (100 mM NaCl, 25 mM NaPO4, pH 7.4), mechanical harvesting
of cells using a rubber policeman, and centrifugation of healthy, con-
fluent cells from the suspension for 5 min at 1,000  g. The cell pellets
were then resuspended and homogenized in ice-cold NP buffer (200
l/confluent plate) supplemented with complete protease inhibitor mix-
ture (1 Mini tablet per 10 ml; Roche Diagnostics), followed by centrif-
ugation at 10,000  g for 10 min at 4 °C. After centrifugation, the
supernatant was then discarded and the pellet resuspended in TNP
buffer (NP buffer supplemented with 1% Triton X-100; 200 l per ml of
starting suspension; supplemented with protease inhibitor mixture) by
incubating at room temperature for 30 min. The preparation was then
centrifuged at 12,500  g for 10 min at 4 °C. The supernatant fraction
containing the solubilized membrane protein was then collected, and
separate samples were reacted overnight at 4 °C with either H133
(rabbit anti-nAChR 4 subunit) or H92 (rabbit anti-nAChR 2 subunit)
antibodies (both from Santa Cruz Biotechnology, Santa Cruz, CA; 5
g/1 mg of solubilized total membrane protein) in the presence of
protein G-agarose beads (50 l; Calbiochem). Immunoprecipitants were
collected by centrifugation, and the beads containing immune com-
plexes were washed 3 times in TNP buffer before being resuspended in
SDS-PAGE sample buffer containing -mercaptoethanol (20 l per
sample; ICN Biomedicals), heated to 95 °C for 3 min, and centrifuged
briefly to remove the stripped agarose beads. The now-resolubilized
protein samples were then collected and subjected to SDS-PAGE sepa-
ration on 10% acrylamide gels and transferred to nitrocellulose mem-
brane for Western analysis. Membranes were then blocked by PBS
buffer containing 5% skim milk powder and incubated with primary
monoclonal antibody 299 (rat anti-nAChR 4; 1:1000; Sigma) and pAb
s-1724 (rabbit anti-nAChR 2; 1:50; a gift from Dr. J. Patrick, Baylor
College of Medicine, Houston, TX) for 1 h. After three 5-min washes in
PBS containing 0.05% Tween 20, secondary horseradish peroxidase-
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conjugated, goat anti-rat IgG (sc-2006) and donkey anti-rabbit IgG
(sc-2313) antibodies (1:1000; Santa Cruz Biotechnology) were added to
the reaction medium to allow conjugation with subunit-primary anti-
body targets. The horseradish peroxidase:second antibody-labeled
bands were then visualized by using enhanced substrate Opti-4CN
(Bio-Rad). Earlier control studies had demonstrated that there was no
cross-reactivity on the nitrocellullose membranes between monoclonal
antibody 299 and 2 subunits, between pAb s-1724 and 4 subunits,
between secondary antibodies and nAChR subunits, or between goat
anti-rat IgG antibody and any residual rabbit antibodies in immuno-
precipitates (although cross-reactivity between donkey anti-rabbit IgG
and rabbit antibodies carried over from immunoprecipitations was
sometimes observed), ensuring that nAChR 4 and 2 subunits could
be identified on the same Western blot when probed with both subunit-
specific antibodies and both species-specific anti-IgG.
Patch Clamp Whole Cell Current Recordings—Conventional whole
cell current recording, coupled with techniques for fast application and
removal of drugs (U-tube), was applied in this study as previously
described (38–40). Briefly, cells plated on poly-lysine-coated 35-mm
culture dishes were placed on the stage of an inverted microscope
(Olympus iX7, Lake Success, NY) and continuously superfused with
standard external solution (2 ml/min). Glass microelectrodes (3–5 M
resistance between pipette and extracellular solutions) were used to
form tight seals (2 G) on the cell surface until suction was applied to
convert to conventional whole cell recording. Cells were then voltage-
clamped at a holding potential of 60 mV, and ion currents in response
to application of ligands were measured (Axon Instruments 200B am-
plifier, Foster City, CA), typically using data filtered at 2 kHz, acquired
at 5 kHz, displayed and digitized on-line (Axon Instruments Digidata
1200 series A/D board), and stored on hard media for subsequent
off-line analysis. Both pipette and whole cell current capacitance were
minimized, and the series resistance was routinely compensated to
80%. Before series resistance compensation, whole cell access resist-
ance less than 20 M was accepted. Data acquisition and analyses were
done using Pclamp8.0 (Axon Instruments), and results were plotted
using Origin 5.0 (Microcal, North Hampton, MA). nAChR acute desen-
sitization (the decline in inward current amplitude over the course of
agonist application) was analyzed for decay half-time (;   0.693/k for
decay rate constant k), peak current (Ip), and steady-state current (Is),
using fits to the mono- (or double-) exponential expression I  [(Ip  Is)
ekt] 	 Is (or I  [(Ip  Ii) e
k1t] 	 [(Ii  Is) e
k2t] 	 Is, where Ii is the
intermediate level of current and k1 and k2 are rate constants from the
two separate decay processes). Curve fitting usually was done using
data between 90 and 10% of the difference between peak and steady-
state currents. The experimental data are presented as mean  S.E.,
and comparisons of different conditions were analyzed for statistical
significance using Student’s t tests. All experiments were performed at
room temperature (23  1 °C). Dose-response profiles were fit to the
Hill equation and analyzed using Origin 5.0.
Solutions and Drug Application—The standard external solution
contained 120 mM NaCl, 3 mM KCl, 2 mM MgCl2, 2 mM CaCl2, 25 mM
D-glucose, 10 mM HEPES, adjusted to pH 7.4 with Tris base. For
conventional whole cell recordings, “Tris	 electrodes” were used to
prevent receptor functional run-down (37, 40), and were filled with
solution containing 110 mM Tris phosphate dibasic, 28 mM Tris base, 11
mM EGTA, 2 mM MgCl2, 0.1 mM CaCl2, 4 mM Na-ATP, pH 7.3 (41). To
initiate whole cell current responses, nicotinic agonists were delivered
into the bath medium near the cell being recorded via a computer-
controlled U-tube system so that solution exchange occurred within 20
ms (based on 10–90% peak current rise times). Intervals between drug
applications (3 min) were adjusted specifically to ensure stability of
nAChR responsiveness (without functional rundown). Drugs used in
FIG. 1. Heterologously expressed human 42-nAChRs in the SH-EPI cell lines. A, RT-PCR analysis of GAPDH (lane c) or nAChR 4 or
2 subunit messenger RNAs from transfected SH-EPI-h42 cells (42) or from untransfected SH-EP1 host cells (W.T.) were performed as
described under “Experimental Procedures.” The RT-PCR products were electrophoretically resolved on a 1% agarose gel along with a 100-bp
ladder molecular weight marker. GAPDH serves as a positive control, indicating success of RT-PCR analysis, and specificity of 4 and 2 subunit
expression only in transfected cells also is demonstrated. B, in situ hybridization showing expression of nAChR 4 and 2 subunit transcripts in
the SH-EP1-h42 cell line. Following the protocol described under “Experimental Procedures,” cells were probed either with biotinylated 4 or
2 sense orientation riboprobes (a and b, respectively) or with biotinylated antisense 4 or 2 riboprobe (a and b, respectively). The hybridized
probes were then labeled with avidin-Alexa 488, and the signal was subjected to epifluorescence microscopic analysis. Images were obtained at
200 (a and a) or 600 (b and b) magnification (calibration bars are 20 and 50 m, respectively). C, immunoprecipitation-Western analysis
showing nAChR 4 and 2 subunit expression and co-assembly in SH-EP1-h42 cells. Membrane fractions from untransfected SH-EP1 cells
(lanes 2 and 4) or SH-EP1-h42 cells (lanes 1 and 5) were detergent solubilized and subjected to immunoprecipitation using anti-4 antibody
(lanes 1 and 2) or anti-2 antibody (lanes 4 and 5) before being subjected to SDS-PAGE, vacuum blotting, and Western analyses for both nAChR
4 subunit (70 kDa band; compare with pre-stained SDS-PAGE mass standards in lane 3 having sizes indicated to the left of the image) and 2
subunit (52-kDa band) proteins. The faint band of 55 kDa in lanes 2 and 4 is not reproducibly observed and likely reflects cross-reaction of
donkey anti-rabbit IgG with primary rabbit anti-subunit antibodies sometimes carried over into the sample. D, wild-type, untransfected SH-EP1
cells (blue arrow) or SH-EP1-h42 cells heterologously expressing human 4 and 2 subunits (black arrow) were tested for whole cell current
responses to 1 M nicotine applied for 4 s. No response was observed in wild-type cells, but an inward current was rapidly induced in transfected
cells.
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the present study were () nicotine, dihydro--erythroidine (DHE),
A40–1 (Sigma), and A1–42 (rPeptide, Athens, GA). A peptides were
reconstituted per vendor specifications in distilled water to a concen-
tration of 100 M, stored at 20 °C, and used within 10 days of recon-
stitution. Thawed peptide solutions and working dilutions in standard
extracellular solution were used within 4 h before being discarded.
RESULTS
Heterologously Expressed h42-nAChRs in SH-EP1 Cells—
RT-PCR analysis confirmed expression of nAChR 4 and 2
subunit messages in SH-EP1-h42 cells (Fig. 1A; 42). By
contrast, whereas there was successful amplification of
GAPDH message (positive control, lane c), no significant 4- or
2-specific product was observed in the host cell line (wild-type
SH-EP1 cells). Results of in situ hybridization studies consis-
tently found an absence of staining for nAChR 4 or 2 subunit
messages reacting with sense or antisense riboprobes in un-
transfected SH-EP1 host cells (data not shown) or reacting
with sense riboprobes in SH-EP1-h42 cells (Fig. 1B, a and b).
However, for reactions employing antisense riboprobes, nearly
all SH-EP1-h42 cells displayed strong perinuclear and cyto-
plasmic hybridization signals for both 4 and 2 subunits (Fig.
1, B, a and b), respectively. Furthermore, apparent levels of
4 or 2 subunit transcripts did not seem to fluctuate as a
function of cell confluence or between grouped or solitary cells
(data not shown). Immunoprecipitation-Western analyses us-
ing solubilized membrane samples from transfected SH-EP1-
h42 cells clearly indicated that 4 and 2 subunits are
expressed as protein and assembled together (Fig. 1C). Finally,
screening using whole cell current recordings confirmed that
functional responses to 1 M nicotine are evident in transfected
SH-EP1-h42 cells, but not in untransfected, wild-type SH-
EP1 cells (Fig. 1D), indicating that transfected cells express
functional h42-nAChRs.
Basic Functional Properties of Transfected h42-nAChRs—
Whole cell current responses of heterologously expressed
h42-nAChRs show nicotine and acetylcholine (ACh) dose
dependence (Fig. 2A) that translates into a sigmoid dose-re-
sponse relationship characterized by a functional EC50 value
for nicotine of 3.2 M (Hill coefficient of 0.81) and for ACh of 9.2
M (Hill coefficient of 0.6; Fig. 2B). Voltage dependence of
h42-nAChR responses to both nicotine and ACh (Fig. 2B)
shows inward rectification at positive membrane potentials
(Fig. 2C). Nicotine dose-response curves for h42-nAChR-
mediated currents obtained in the presence of 0.3 or 1 M
DHE, which is a relatively selective antagonist of 42-
nAChRs compared with other nAChR subtypes, are shifted to
the right without showing an effect on peak whole cell current
amplitude at maximal nicotine concentration (Fig. 2D). Com-
pared with the EC50 value for nicotine alone (3.3  0.6 M,
mean  S.E. for separate EC50 measures from replicate exper-
iments, n  10), the EC50 obtained for nicotine in the presence
of 300 nM DHE is higher, but not significantly (4.7  1.2 M,
FIG. 2. Basic functional properties of transfected human 42-nAChRs. A, nicotine- and ACh-induced inward currents were obtained at
different concentrations indicated along the horizontal bars showing the time course for drug application above each trace. At a high nicotine
concentration (1 mM), washout of nicotine induced a rebound current (indicated by arrow). B, concentration-response relationship curves for
nicotine and ACh. All symbols were normalized to current induced by 100 M nicotine exposure (shown by the arrowhead). Each data point is the
average from 6 to 8 cells tested, and the vertical bars indicate standard errors. C, 100 M nicotine- and 1 mM ACh-induced inward currents at
different holding potentials are superimposed. The current-voltage relationship curves for both nicotine and ACh responses show a clear inward
rectification. All peak currents induced by agonists were normalized to the agonist responses at a holding potential of 60 mV (marked with the
arrowhead). Each symbol is the average response from 7 to 8 cells. D, the sigmoidal nicotine concentration-peak current response curves in the
absence or presence of 300 nM or 1 M DHE show that DHE shifted the nicotine concentration-response curve to the right without affecting the
maximal response, suggesting a competitive mechanism of antagonism. All symbols were normalized to the 100 M nicotinic response (marked with
the arrowhead), and each symbol is the average from 4 to 8 cells.
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p  0.05, n  11), but the EC50 obtained in the presence of
nicotine plus 1 M DHE is significantly higher (9.6  1.5 M,
p 
 0.05, n  4), but nicotine efficacy is not reduced in the
presence of DHE. Thus, DHE exhibits features of competi-
tive antagonism acting on heterologously expressed h42-
nAChRs. These basic electrophysiological and pharmacological
properties indicate that heterologously expressed h42-
nAChRs in SH-EP1 cells exhibit characteristic features of the
subtype and validate SH-EP1-h42 cells as models for study-
ing h42-nAChR function.
A1–42 Acutely Inhibits h42-nAChR-mediated Whole Cell
Currents—Initial studies done to examine the acute effects of 1
nM A1–42 on h42-nAChR responses to nicotine or ACh in-
dicated that pretreatment (typically done for 3 min) with A
peptide was necessary to elicit a statistically significant, func-
tional inhibition of peak current responses (reduced to 75.3 
2.1% of control values for nicotine, n  18, p 
 0.01; reduced to
77.4  3.1% of control values for ACh, n  8, p 
 0.01; Fig. 3,
A and B). A1–42 exposure also caused reduction of steady-state
whole cell current responses to nicotine (reduced to 75.5 2.2%
of control values, n  18, p 
 0.01) or ACh (reduced to 71.5 
4.2% of control values, n  8, p 
 0.01; Fig. 3, A and B).
Increases in rates and extents of acute desensitization, as-
sessed as time constants for inward current decay from peak to
steady-state levels and as the magnitude of the steady-state
inward current, were evident for A1–42 action on h42-
nAChRs responding to nicotine or ACh (Fig. 3A, traces). Be-
cause there were no differences in effects of A1–42 on ACh- or
nicotine-induced h42-nAChR function, the remainder of the
studies focused on the use of nicotine as the prototypical nico-
tinic agonist. Interestingly, without pretreatment, 1 nM A1–42
did not show significant reduction of peak current responses to
nicotine (decreased to 94.3 2.9% of control values, n 17, p
0.05), but the peptide reduced steady-state currents to 76 
6.0% of control values (n  17, p 
 0.01; data not illustrated).
Studies using the reverse-sequence peptide A40–1 failed to
show significant inhibition of h42-nAChR function (data also
not illustrated), suggesting that effects were peptide sequence-
specific. An additional set of studies examining the effects of
different concentrations of A1–42 on responses to 1 M nicotine
showed dose-dependence of h42-nAChR functional block
(Fig. 3, C and D). Collectively, these results indicate that
A1–42 acutely inhibits h42-nAChR function.
Possible Mechanisms Involved in A1–42 Inhibition of h42-
nAChR Function—Dose-response profiles of nicotine-induced
whole cell peak currents in the absence or presence of 1 nM
A1–42 showed similar magnitudes of peptide-induced func-
tional inhibition and no dramatic change in nicotine EC50 val-
ues or Hill coefficients (3.3  0.6 and 0.97  0.07 M, respec-
tively, for nicotine alone, n  10; 4.1  0.9 and 1.1  0.1 M,
respectively, for nicotine plus 1 nM A1–42, n  5, p  0.05),
suggesting a non-competitive mechanism of inhibition (Fig. 4,
A and B). Other studies indicated that 1 nM A1–42 showed
similar inhibition of 100 M nicotinic-induced responses at
different holding potentials (VH), suggesting a voltage-indepen-
dent means of functional inhibition by A1–42 (Fig. 4, C and D).
A repeated application protocol with nicotine in the continuous
presence of 1 nM A1–42 demonstrated that 1 nM A1–42 did not
FIG. 3. A1–42 acutely modulates human 42-nAChR-mediated currents. A, comparison of effects of 1 nM A1–42 on nicotine- and
ACh-induced currents. Whole cell current response traces recorded from the same cell for A and B, and from another cell for C and D. B, bar graph
summarizing results (peak and steady-state currents) from replicate studies. The horizontal dashed line indicates the control value (100%) for the
specified parameter for the nicotinic response (induced by 1 M nicotine and 10 M ACh) before A1–42 treatment. Double asterisk means p 
 0.01.
C and D, concentration-dependent inhibition by A1–42 of h42-nAChR function induced by 1 M nicotine is shown as individual traces recorded
from the same cell (C), and results for the indicated parameters from replicate studies are summarized in D. In all recordings (A and C), the cells
were held at a holding potential (VH) of 60 mV. In D, the asterisk means p 
 0.05, the double asterisk means p 
 0.01, and the triple asterisk
means p 
 0.001. Vertical bars indicate standard errors.
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show clear signs of use-dependent inhibition of h42-nAChRs
(Fig. 5, A and C). Interestingly, after 15 min of continuous
exposure to 1 nM A1–42 followed by peptide washout for 6 min,
peak current responses to nicotine did not recover fully (Fig. 5,
A and C). The absence of use-dependence suggests that non-
competitive inhibition of h42-nAChR function by A1–42 is
not mediated through open channel block, although the per-
sistence in functional block after washout of fluid phase A
suggests a lingering effect of the peptide (see “Discussion”). To
address whether A1–42-induced h42-nAChR internalization
is involved in this incomplete functional recovery after rela-
tively long term exposure (15 min) of h42-nAChRs to 1 nM
A1–42, we pre-loaded recorded cells with GDPS (600 M) for
20 min, which was reported to prevent -amino-3-hydroxy-5-
methyl-4-isoxazolepropionate receptor endocytosis (42), and we
repeated the experiment shown in Fig. 5A. GDPS treatment
neither prevented A1–42-mediated inhibition, nor improved
h42-nAChR functional recovery from washout of A1–42
(Fig. 5, B and C), suggesting that the inhibition of h42-
nAChR function by A1–42 is not mediated via h42-nAChR
internalization through the process affecting -amino-3-hy-
droxy-5-methyl-4-isoxazolepropionate receptors.
Acceleration of h42-nAChR Acute Desensitization by
A1–42 Is Not Influenced by 2 Subunit Intracellular Do-
mains—The data presented thus far indicate that 1 nM A1–42
accelerates h42-nAChR desensitization. We considered
whether this modulation could be via mechanisms involving
sequences in the nAChR 2 subunit large, cytoplasmic loop
that are potentially involved in nAChR phosphorylation (46),
possibly engaged in coupling to the cytoskeleton or cytoplasmic
modulators, or perhaps involved in some other intracellular
mechanism mediating A1–42 action. To test these possibilities,
we created chimeric 2 (2ch) subunits whose natural cytoplas-
mic loop sequences were replaced by those from the mouse
serotonin receptor 5-TH3A subunit sequence. 42ch-nAChR-
mediated currents showed significant acceleration of receptor
desensitization compared with rates of desensitization for fully
wild-type 42-nAChRs (Fig. 6, A and B). However, 1 nM
A1–42 further accelerated receptor desensitization and low-
ered peak and steady-state components of nicotine-induced
whole cell currents in either 42- or 42ch-nAChRs (Fig. 6,
C and D). These results suggest that accelerated 42-nAChR
desensitization upon A1–42 exposure is not influenced by
changes in the nAChR 2 subunit cytoplasmic loop sequence.
Selective Inhibition of h42-nAChR Function at Patho-
physiologically Relevant Concentrations of A1–42—Given re-
ports of interactions at high concentrations (100–3000 nM) of
A1–42 with 7-nAChRs (22, 23, 25, 26) and rat 42-nAChRs
(24), we compared effects of A1–42 on function of heterolo-
gously expressed h42-nAChRs to effects on heterologously
expressed h7-nAChRs expressed in the same cellular host
(40). A1–42, at a pathophysiologically relevant concentration
(1 nM), clearly inhibits nicotinic peak current responses medi-
ated by h42-nAChRs (inhibition to 76% of control values;
Fig. 7A, left), but not responses mediated by h7-nAChRs (Fig.
7B, left). However, at a higher concentration (100 nM), A1–42
inhibits both h42-nAChR- (to 68% of control values; Fig. 7A,
right) and h7-nAChR-mediated peak currents (to 41% of con-
trol values; Fig. 7B, right), although the magnitude of func-
tional inhibition of 7-nAChRs is greater. Interestingly, the
FIG. 4. A1–42 inhibits human 42-nAChR-mediated currents in a non-competitive and voltage-independent manner. A, individual
whole cell current traces for responses to nicotine at the indicated concentrations alone (higher amplitude traces) or in the presence of 1 nM A1–42
(smaller amplitude traces). B, results of replicate studies (as in A) fit to the logistic equation indicate a downward shift reflecting reduction of
maximal current response in the agonist dose-response profile in the presence of A1–42, but without a change in apparent EC50 for agonist,
characteristic of non-competitive inhibition. All symbols were normalized to the peak current induced by 100 M nicotine (marked by the
arrowhead), and each symbol is the average from 10 cells for nicotine, and 5 cells for nicotine plus 1 nM A1–42. C, representative whole cell current
traces in response to 100 M nicotine alone (higher amplitude traces) or in the presence of 1 nM A1–42 (lower amplitude traces) at different holding
potentials as indicated. D, plots of whole cell peak current amplitude as a function of holding potentials. All symbols were normalized to
nicotine-induced peak current at a VH of80 mV (marked by the arrowhead) and are averages of recordings from 5 to 6 cells. Vertical bars indicate
standard errors.
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inhibition of h42-nAChR-mediated currents by 1 or 100 nM
A1–42 appears to occur through different mechanisms because
1 nM A1–42 accelerated the rate of current decay from peak to
steady-state levels without changing the half-time for achieve-
ment of peak currents, whereas 100 nM A1–42 slowed current
rising time without changing decay time (Figs. 3D and 7, A and
C). Nevertheless, these results indicate that heterologously
expressed h42-nAChRs are more sensitive than h7-
nAChRs to pathophysiologically relevant concentrations (1 nM)
of A1–42.
DISCUSSION
Principal Observations—These studies validate SH-EP1-
h42 cells as a model for investigation of the properties of
h42-nAChRs. The cells express nAChR 4 and 2 subunits
as mRNAs and receptor subunit proteins that co-assemble to
yield nAChRs that show functional responses to nicotine or
ACh that are sensitive to competitive inhibition by DHE and
that are manifest as inwardly rectifying whole cell currents on
patch clamp analysis. A1–42 peptides, but not control A40–1
peptides, inhibit function of h42-nAChRs at concentrations
as low as 1 nM. Effects are manifest as a reduction in whole cell
peak and steady-state currents and acceleration of rates of
desensitization. Effects show no use-dependence or voltage-
dependence and persist after bulk removal of peptide in solu-
tion. Features of functional inhibition are the same for 42-
nAChRs and nAChRs composed of 4 subunits and a chimeric
form of 2 subunits containing alternate cytoplasmic loop
amino acids. A1–42-mediated inhibition of human 7-nAChR
function also is observed, but at higher concentrations (100 nM).
nAChR Subtype Selectivity of AEffects and Effective Doses—
When we began these studies, there were some points of con-
troversy in the earlier literature concerning A/nAChR inter-
actions. Liu et al. (23) reported that 100 nM A1–42 suppressed
7-nAChR-mediated currents but failed to block peak whole
cell current responses attributed to non-7-nAChRs expressed
on cultured rat hippocampal neurons. By contrast, Pettit et al.
(22) found that 2 M A1–42 inhibited single channel opening
probability of both 7- (38 pS channel; by 14%) and, more
potently, non-7- (62 pS channel, by 54%) nAChR-mediated
currents recorded from excised membrane patches derived
from rat hippocampal slices. Although the non-7-nAChR sub-
types studied by Liu et al. (23) and Pettit et al. (24) were not
specifically identified, studies of heterologously expressed rat
42-nAChRs in Xenopus oocytes revealed that 10-min pre-
treatment with 100 nM A1–42 depressed peak whole cell cur-
rents to 62% of control levels while having a much smaller
effect on rat 7-nAChRs (24). Heterologously expressed (in
oocytes) human (25) or rat (26) 7-nAChRs are functionally
blocked by preincubation with 100 nM A1–42. However, oocyte-
expressed rat 7-nAChR responses are reported to be activated
by the initial application of 1–100 pM A1–42 (26). Other studies
using acutely dissociated, rat basal forebrain neurons indicated
FIG. 5. Mechanisms involved in A1–42 inhibition of human 42-nAChR-mediated currents. A, representative whole cell current traces
recorded using normal Tris solution-filled pipettes. 1 M nicotine was repetitively applied (4-s exposure at an interval of 3 min). The first three
responses were recorded as controls, then nicotine exposures were repeated at 3-min intervals in the continuous presence of 1 nM A1–42 for 15 min,
and then an additional response to nicotine was recorded after 6 min of washout of A1–42. B, representative whole cell current traces recorded
using Tris-filled pipettes supplemented with 600 M GDPS. Initial responses to nicotine were measured after 20 min of intracellular GDPS
exposure, and the sequence of drug applications was as described in A. C, temporal patterns show the similar effects of 1 nM A1–42 on nicotinic
responses with and without GDPS in the pipette solution. The asterisk means p
 0.05, the double asterisk means p
 0.01, and the triple asterisk
means p 
 0.001. Vertical bars indicate standard errors.
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that 4 M A25–35 or 100 nM A1–42 directly activated single
channels and that 10 or 100 nM A1–42 induced whole cell
current responses attributable to a non-7-nAChR subtype
(likely 42-nAChR), also suggesting agonist-like activity of
A on nAChRs (43). Our observations showing (for the first
time) significant functional inhibition of h42-nAChRs by 1
nM A1–42 and finding (consistent with cross-species observa-
tions) (22–26) inhibition of h7-nAChRs by 100 nM A1–42
indicate that A1–42 acts as a nAChR functional antagonist
with higher affinity for h42-nAChRs than for h7-nAChRs.
Doses at which confirmed, high affinity, nicotine-binding
h42-nAChRs are affected by A1–42 are in the range of
peptide concentrations of potential pathological relevance, i.e.
similar to those (0.01–5 nM) found in AD patient cerebrospinal
fluid (44, 45).
Possible Mechanisms of A1–42-mediated Inhibition of
h42-nAChR Function—The present results clearly support
the hypothesis that A directly modulates nAChR function.
Our data shows that A1–42, at concentrations from 1 pM to 1
M, failed to directly induce whole cell current responses from
cells expressing h42- or h7-nAChRs or from untransfected
cells, meaning that A, in our hands, and although signal
transduction through other means remains a possibility, does
not have properties of a nAChR agonist able to induce whole
cell currents. This finding is in agreement with previous re-
ports that A1–42 failed to elicit naturally expressed 7-
nAChR-mediated currents in cultured hippocampal neurons
(23) or heterologously expressed 7-nAChR responses in Xeno-
pus oocytes (25), but it is not consistent with A1–42 binding to
rat 7- or non-7-nAChRs (likely 42-nAChRs) at an agonist,
co-agonist, or other allosteric, positive modulatory site involved
in eliciting or enhancing whole cell currents (26, 43). Agonism
(or competitive antagonism) also is inconsistent with our re-
peated findings2 failing to detect direct competition of picomo-
lar to micromolar A1–42 with radioligand binding sites on
heterologously expressed h42- or h7-nAChRs. On the con-
trary, our findings indicate that A1–42 acts as a non-compet-
itive antagonist of h42-nAChRs under our experimental con-
ditions. A non-competitive mechanism of naturally or
heterologously expressed 7-nAChR functional block by A1–42
also has been invoked (22, 25).
As to the domain(s) involved in non-competitive block, our
data indicating that effects of A1–42 on h42-nAChR func-
tion are not affected by changes in amino acid sequences cor-
responding to the 2 subunit second, major intracellular do-
main, suggests an alternate site of action. Other chimera
studies of 7-nAChRs more directly indicated a role for the
NH2-terminal extracellular domain of the 7 subunit in A
effects on that subtype (23). Our data showing no use or voltage
dependence of A1–42 inhibition of h42-nAChR function sug-
gests that effects are not mediated via open channel block. In
2 S. Morrissy, L. H. Wilkins, Jr., K. M. Schroeder, and R. J. Lukas,
unpublished data.
FIG. 6. A1–42 inhibits both wild-type h42-nAChR- and h42-chimera-nAChR-mediated currents. A, representative whole cell
current traces for responses to 1 M nicotine (a) or 1 mM ACh (b) of fully wild-type h42-nAChRs and nAChRs containing wild-type 4 and
chimeric 2 subunits (42-chimera). Right panels superimpose the nicotinic responses from the left and middle panels. B, bar graphs compare 1
M nicotine-induced whole cell currents recorded from transfected wild-type h42-nAChRs and 42-chimera-nAChRs. The normalized wild-type
h42-nAChR-mediated currents (as 100%) are presented as a horizontal dashed line. Ip and Is mean the peak and steady-state currents,
respectively. C, representative whole cell current traces for responses to 1 M nicotine alone or in the presence of 1 nM A1–42 (lower amplitude
traces) for wild-type h42-nAChRs (a) or for 42-chimera-nAChRs (b). D, summary of effects of 1 nM A1–42 on peak and steady-state current
amplitudes and on fast and slow phases of nAChR desensitization in 4–14 replicate studies. The asterisk means p 
 0.05 and the triple asterisk
means p 
 0.001. Vertical bars indicate standard errors.
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agreement with other studies (23–26), we also found that pre-
treatment with A1–42 is necessary to induce convincing inhi-
bition of h42-nAChR-mediated nicotinic responses. The na-
ture of this slow onset of inhibition is still unknown, although
it has been hypothesized that A1–42 may drive nAChRs into a
long-lived closed conformation. This hypothesis is supported by
the present observation that long exposure (15 min) to A1–42
led to persistent loss of h42-nAChR function, although any
loss of nAChR function does not seem to be mediated via
A1–42-induced h42-nAChR internalization. Our finding
that A1–42 exposure accelerated rates of h42-nAChR func-
tional desensitization is consistent with another report that
A1–42 accelerated the rate of current decay for muscle-type
nAChRs (25). A possible role of changes in nAChR phosphoryl-
ation state in regulation of receptor desensitization has been
proposed (46), but our studies suggest that any such role for
h42-nAChR phosphorylation would be because of changes in
4 subunit phosphorylation state.
Pathological Relevance of 42-nAChR Dysfunction and
AD—nAChRs that bind radiolabeled nicotine with the highest
affinity contain 4 subunits (4*-nAChR; for review, see Refs.
47–51). Immunoassays have shown that the predominant, nat-
urally expressed form of the 4*-nAChR in the vertebrate brain
contains 4 and 2 subunits (42-nAChR) (17, 18). Evidence
indicates that a consistent, significant loss of 4*-nAChRs has
been observed at autopsy in a number of neocortical areas and
hippocampi of patients with AD (for reviews, see Refs. 52 and
53). Cortical 4*-nAChR deficits are significantly correlated
with cognitive impairment in AD patients (54, 55). The major
pathological features of AD are A protein deposition and a
severe cholinergic deficit. It has been shown that A protein
serves as a major constituent of senile plaques, a neuropatho-
logic hallmark of AD and a neurotoxin through in vivo and in
vitro studies. A1–42 accumulation and aggregation are
thought to contribute to the pathology of AD. However, links
between soluble A1–42 elevation and cholinergic dysfunction
remain unclear. The present studies provide the basis for a new
hypothesis that A1–42-induced h42-nAChR functional de-
pression may contribute to cholinergic signaling deficits and/or
neurodegeneration that are hallmarks of AD. This hypothesis
is not necessarily exclusive of, for example, other mechanisms
that would produce selective death of cholinergic neurons,
would result in destabilization of membrane properties by A
and/or its precursors (56–59), or would reflect effects of A on
intracellular Ca2	 homeostasis through either production of
cation ionophores or activation of ligand- and/or voltage-gated
channels (60, 61). Our perspective on a primary role for h42-
nAChRs in low concentration effects of A complements other
suggestions that the modulation of nAChR function by A
could be pathologically relevant (20–26, 43).
In conclusion, this study provides evidence for a possible link
between abnormal deposits of A1–42 and h42-nAChR dys-
FIG. 7. 1 nM A1–42 selectively inhib-
its human 42- but not human 7-
nAChR-mediated currents. A, repre-
sentative whole cell current traces
comparing effects of 1 nM (left) and 100 nM
(right) A1–42 on function of 42-
nAChRs showing functional inhibition of
comparable magnitude at both concentra-
tions, but slower activation (rising time)
kinetics in the presence of 100 nM peptide.
Note the different time scales in the pairs
of traces allowing for clearer resolution of
rising phases in the right-hand traces. B,
representative whole cell current traces
comparing effects of 1 (left) and 100 nM
(right) A1–42 on function of 7-nAChRs
showing functional inhibition only at 100
nM. Note the different time scales in the
pairs of traces allowing for clearer resolu-
tion of rising phases in the right-hand
traces. C, bar graph summarizing obser-
vations of effects of 1 or 100 nM A1–42 on
the peak component and rising time to
peak current for responses mediated by
human 42-nAChRs (filled bars) or 7-
nAChRs (open bars). The asterisk means
p 
 0.05 and the double asterisk means
p 
 0.01. Vertical bars indicate standard
errors.
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function in AD patients. Furthermore, the finding that human
42-nAChRs are sensitive targets of pathophysiologically rel-
evant concentrations of A1–42 suggests novel strategies for AD
therapy that would involve amelioration of peptide-induced
42-nAChR functional block and/or perhaps preservation of
42-nAChR activity.
Acknowledgment—We thank J. Brek Eaton for maintenance of SH-
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